India Oncology Therapeutics Market Examined in New GBI Research Report Recently Published at

India Oncology Therapeutics Market Examined in New GBI Research Report Recently Published at

MarketPublishers, Ltd.Tanya RezlerTel: +44 208 144 6009Fax: +44 207 900 3970

In 2011, India’s oncology therapeutics market for breast cancer, colorectal cancer, lung cancer, NHL and prostate cancer was evaluated at USD 153.3 million, showing a CAGR of around 3 percent from 2004.

In 2018, it is forecast to amount to almost USD 240 million, up by approximately 7 percent from 2011 given the decrease in prices for the most popular products. Restrictive reimbursement and pricing policies, weak infrastructure and support from governments, and low patient affordability are among the factors limiting the market growth.

New market research report developed by GBI Research offers a comprehensive guide to the Indian oncology therapeutics market. The report provides insightful overview of the market, treatment usage patterns, top M&A trends in the breast cancer, colorectal cancer, prostate cancer, lung cancer as well as NHL markets. The study scrutinizes therapeutic landscape and the competitive environment. The research report contains pipeline analysis and annualized market data for the oncology therapeutics market from 2004 to 2011; reviews market igniters and barriers; contains future market outlook to 2018.


Published: April 8, 2013

Pages: 88

Price: US$ 3,500.00

More new market research reports by GBI Research can be found at

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.